AHA Statement Supporting CCTA for CAD Diagnosis in Diabetic Patients

In everything that we do as clinicians, the search for better options, treatments, or paths for our patients is constant.  For patients with type 2 diabetes mellitus (T2DM), this need for a better option regarding cardiovascular disease is profound.

Cardiologists have long understood that patients with T2DM are likely to experience more aggressive cardiovascular disease development and progression than are patients with other comorbidities.  Publications focusing on the need to serve these patients better came back to back this month with a scientific statement from the American Heart Association and an expert analysis from the American College of Cardiology both focused on evaluating and managing these challenging patients.

One element that caught my attention in both publications was discussion and direction around improving identification of stable CAD in patients with T2DM, especially those with new onset of chest pain.  Relying on data from ISCHEMIA, SCOT-HEART, and PROMISE, there is a clear message that the use of standard stress testing to diagnose CAD may not be the best option for these patients.

Much has been written about how the ISCHEMIA trial findings force clinicians to rethink the utility of systematic stress testing, especially in terms of risk stratification and identification of patients who may benefit from revascularization.  Those same learnings become even more impactful as we consider that 41% of ISCHEMIA participants had diabetes.

PROMISE found that patients with T2DM who were assessed with coronary CTA had a much lower CV event rate than those assessed with functional stress testing, and the findings in SCOT-HEART for patients with T2DM echoed this same message.  It appears that the combination of these and other data led to this recommendation in the AHA Scientific Statement published this month:

“Overall, CTA may provide an advantage over stress testing in the management of patients with T2DM and stable angina, mostly for its ability to diagnose non-obstructive CAD and therefore inform medical management.”

This move toward coronary CTA is in line with guidelines and guidance from clinical societies, provider organizations, and healthcare payers around the world.  With all that is changing now, it seems reasonable to believe that the movement to coronary CTA for CAD diagnosis will become more pronounced as it uniquely provides a combination of diagnostic confidence, prognostic insights, patient-provider safety, and CT-derived lesion-specific physiology.

Read the Statement

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.